This review concluded that trimetazidine may have decreased hospitalisation for cardiac causes, improved clinical symptoms and cardiac function, and ameliorated left ventricular modelling in patients with chronic heart failure. Despite some uncertainties in the methods used to select studies, the authors cautious conclusions reflect the evidence presented and are likely to be reliable.
The included studies used trimetazidine at 60mg or 70mg per day. The New York Heart Association functional class of included patients ranged from I to IV where reported. The percentage of included patients with ischaemic aetiology ranged from zero to 100%. Most included patients were male. The mean left ventricular ejection fraction at baseline ranged from 29 to 55%. The duration of follow-up ranged from one to 23 months. The mean age of patients ranged from 50 to 78 years.
The authors did not report how many reviewers assessed studies for inclusion.
Assessment of study quality
The quality of studies was assessed using the Jadad scale, a five-point scale evaluating randomisation, blinding and withdrawals/drop-outs.
Two reviewers independently performed study quality.
Data extraction
For continuous outcomes, data were extracted on mean and standard deviations to enable the calculation of mean differences (MDs) with 95% confidence intervals (CIs). For dichotomous outcomes, data were extracted on event rates to enable the calculation of relative risks (RRs) with 95% confidence intervals.
Two reviewers independently performed data extraction.
Methods of synthesis
The studies were combined in a meta-analysis. The weighted mean differences (WMDs) and standardised mean differences (SMDs) with 95% confidence intervals were calculated. The pooled relative risks with 95% confidence intervals were also calculated. A random-effect model was used when there was significant heterogeneity; otherwise a fixed-effect model was employed. Statistical heterogeneity was assessed using Ι². Meta-regression was used to assess the influence of age, aetiology, baseline left ventricular ejection fraction, type of trimetazidine, baseline New York Heart Association functional class and length of follow-up. Sensitivity analyses were performed by excluding one study at a
